Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Aug 15, 2021; 13(8): 845-855
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.845
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.845
Table 1 First and second-line treatments for advanced hepatocellular carcinoma
| Systemic treatment | Drug selection | |
| First-line drugs | Second-line drugs | |
| Targeted therapy | Sorafenib; Lenvatinib; Donafenib | Regorafenib; Cabozantinib; Apatinib |
| Immunotherapy | Nivolumab; Pembrolizumab | Camrelizumab; Ramucirumab; Durvalumab |
| Combination therapy | Atezolizumab + Bevacizumab (Preferred) | Camrelizumab + Apatinib (Phase Ia/Ib) |
| Sintilimab + Bevacizumab analogs (Phase III) | Nivolumab + Ipilimumab (Phase II) | |
| Camrelizumab + Apatinib (Phase II) | Nivolumab + Ipilimumab + Cabozantinib (Phase II) | |
| Sintilimab + Anlotinib (Phase II) | ||
| Tremelimumab + Durvalumab (Phase II) | ||
| Pembrolizumab + Lenvatinib (Phase Ib) | ||
| Anlotinib + Penpulimab (Phase Ib/II) | ||
- Citation: Wang H, Li W. Recent update on comprehensive therapy for advanced hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(8): 845-855
- URL: https://www.wjgnet.com/1948-5204/full/v13/i8/845.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i8.845